LL-37: The Human Cathelicidin Peptide for Immune Defense, Gut Health, and Inflammation

There is a straightforward reason researchers keep returning to vitamin D. The vitamin — more precisely, its hormonally active form, 1,25-dihydroxyvitamin D3 — is one of the few dietary inputs with a direct, well-characterized link to the front-line machinery of innate immunity. When vitamin D3 binds to the vitamin D receptor (VDR) in epithelial cells, neutrophils, and macrophages, it drives transcription of a single gene that encodes a protein called hCAP18. Serine proteases cleave hCAP18 into its active peptide fragment. That fragment is LL-37.

LL-37 is the only cathelicidin antimicrobial peptide expressed in humans. Every other mammal makes a family of cathelicidins — mice make CRAMP, rabbits make CAP-18 — but in the human genome there is exactly one: CAMP, encoding hCAP18, encoding LL-37. The singularity is not a limitation. LL-37 is extraordinarily multifunctional: it kills bacteria directly by punching holes in their membranes, modulates the immune response to prevent both infection and runaway inflammation, reinforces the gut epithelial barrier, accelerates wound healing, and disrupts pathogen biofilms. No other host defense peptide in humans does all five.

The Immune Health Peptides Hub covers the full immune peptide trio — LL-37, Thymosin Alpha-1, and Thymalin — and how they fit together into a layered immune protocol. This article is the deep dive on LL-37 specifically: what it is, how every major mechanism works, what the human research actually shows, and how to use it.

What Is LL-37?

LL-37 is a 37-amino-acid cationic peptide derived from the C-terminus of the precursor protein hCAP18 (human cationic antimicrobial protein of 18 kDa). The "LL" in the name refers to the two leucine residues at the N-terminus of the mature peptide — a structural detail that contributes to its activity.

Biosynthesis. hCAP18 is synthesized and stored in the specific granules of neutrophils, where it represents one of the most abundant granule proteins — roughly 5 µg per million neutrophils (Sorensen et al., 1997). Upon neutrophil degranulation, the serine protease proteinase 3 cleaves the C-terminal domain of hCAP18 to release the mature LL-37 fragment. Epithelial cells in the skin, gut, lung, and urogenital tract also express hCAP18 and process it through cathepsin D and gastricsin-related cleavage depending on tissue context (Johansson et al., 2004).

Structure. LL-37 adopts an alpha-helical conformation in membrane-mimicking environments. This amphipathic helix — with a hydrophilic face carrying positive charge and a hydrophobic face — is the structural basis for both its membrane-disrupting antimicrobial activity and its receptor-binding immunomodulatory effects. The peptide carries a net positive charge of +6 at physiological pH, which allows it to bind avidly to the negatively charged surfaces of bacterial membranes and pathogen-associated molecular patterns like LPS.

Where it is expressed. Primary sources include:

• Neutrophils — the highest-concentration reservoir; LL-37 is released directly at sites of infection
• Keratinocytes — skin surface defense; upregulated by skin injury, UV exposure, and vitamin D
• Intestinal epithelial cells — colonic and small intestinal epithelium; a key determinant of gut barrier defense
• Lung epithelium — airway surface liquid; LL-37 concentration in the lung is a major variable in respiratory infection susceptibility
• Mast cells, monocytes, and NK cells — secondary sources contributing to immune site concentration

Vitamin D3 as the master regulator. The CAMP gene promoter contains a vitamin D response element (VDRE). When 1,25-dihydroxyvitamin D3 binds the VDR, the VDR-RXR heterodimer binds the VDRE and directly drives hCAP18 transcription. The practical implication: vitamin D deficiency is associated with measurably lower LL-37 production, and supplementing vitamin D3 in deficient individuals reliably increases LL-37 expression (Liu et al., 2006). This vitamin D → LL-37 axis is one of the clearest mechanistic explanations for why low vitamin D is associated with increased infection susceptibility and impaired mucosal healing.

Mechanisms of Action

LL-37 operates through five mechanistically distinct pathways. Understanding all five is essential for understanding both its therapeutic potential and the inflammatory paradox that makes it a double-edged molecule.

1. Direct Antimicrobial Activity

LL-37 kills pathogens by disrupting their membranes — but the mechanism is electrostatics before it is force. Bacterial membranes carry a net negative charge due to phosphatidylglycerol and cardiolipin in their outer leaflet. Mammalian cell membranes, by contrast, are predominantly neutral-to-zwitterionic (phosphatidylcholine dominant). LL-37's +6 charge drives selective electrostatic attraction to bacterial membranes and not to host cell membranes.

Once bound, LL-37 inserts into the membrane bilayer and disrupts it via two overlapping models: the carpet model (peptide molecules coat the membrane surface, creating tension until the membrane disintegrates like a wet carpet being pulled apart) and toroidal pore formation (peptide molecules span the bilayer, forming lipid-lined pores that cause ion leakage and loss of membrane potential). The result is rapid bacterial killing — in vitro kill times for susceptible strains are measured in minutes.

Spectrum of activity is broad: gram-positive bacteria (including S. aureus, S. epidermidis, and Enterococcus), gram-negative bacteria (including E. coli, P. aeruginosa, and Klebsiella), fungi (including C. albicans), and enveloped viruses including influenza A (Wang et al., 2014). The membrane-disruption mechanism is non-specific enough that resistance development is slower than with conventional antibiotics — resistance to LL-37 generally requires bacteria to modify their membrane lipid composition, which comes with significant fitness costs.

2. Immunomodulation: The Dual Role

LL-37's immunomodulatory effects are concentration-dependent in a way that explains both its therapeutic value and its inflammatory risk profile.

At low concentrations (nanomolar range), LL-37 is pro-inflammatory: it induces chemokine release — particularly CXCL8 (IL-8) and CCL2 — and drives neutrophil and monocyte chemotaxis to sites of infection (Tjabringa et al., 2003). This is appropriate early-infection signaling: you want immune cells concentrated where the pathogen is.

At higher concentrations (micromolar range), LL-37 becomes anti-inflammatory: it binds and neutralizes LPS (lipopolysaccharide, the primary gram-negative endotoxin), preventing LPS from engaging TLR4. This dampens the TLR4 → NF-κB → cytokine storm cascade that causes sepsis severity. It also downregulates TLR-mediated signaling more broadly, reducing TNF-α and IL-6 production in LPS-stimulated macrophages (Mookherjee et al., 2006).

This bidirectional behavior is why LL-37 dysregulation produces paradoxical outcomes: too little LL-37 (vitamin D deficiency, Crohn's disease epithelium) correlates with increased infection susceptibility; too much LL-37 (rosacea, psoriasis) drives autoimmune-pattern inflammation. The molecule is calibrated, not blunt.

3. Wound Healing

LL-37 drives tissue repair through formyl peptide receptor 2 (FPR2), expressed on keratinocytes and fibroblasts. LL-37 binding to FPR2 activates a signaling cascade that promotes keratinocyte and fibroblast migration into the wound bed — the re-epithelialization step that closes wounds. It also upregulates VEGF (vascular endothelial growth factor) expression in wound-site fibroblasts, driving angiogenesis — the formation of new capillaries that supply the healing tissue with oxygen and nutrients (Koczulla et al., 2003). In chronic wounds where this angiogenic signaling is blunted, LL-37 deficiency at the wound site correlates with poor healing outcomes.

4. Gut Barrier Integrity

LL-37 supports the intestinal epithelial barrier through two mechanisms: direct upregulation of tight junction proteins, and microbiome-mediated effects on barrier function.

At the cellular level, LL-37 increases expression of the tight junction proteins ZO-1 and occludin in intestinal epithelial cell lines (Bhinder et al., 2014). Tight junction integrity is the primary determinant of intestinal permeability — when ZO-1 and occludin expression is maintained, the gut barrier holds. When they're lost (inflammation, dysbiosis, NSAIDs, alcohol), intestinal permeability increases and "leaky gut" develops.

At the microbiome level, high LL-37 expression in the colon is associated with a healthier Bacteroidetes/Firmicutes ratio and reduced pathogen colonization. LL-37's selective antimicrobial activity preferentially suppresses gram-negative pathogens while being somewhat less active against commensal Bacteroidetes. In Crohn's disease, reduced hCAP18/LL-37 expression in colonic epithelium is a consistent finding (Wehkamp et al., 2004) — and is a mechanistic candidate for why IBD patients are more susceptible to mucosal infection and have impaired epithelial repair.

5. Anti-Biofilm Activity

Biofilms — protective polymer matrices that bacteria and fungi use to shield themselves from antibiotics and immune attack — are a major contributor to chronic wound infections and persistent pathogens like P. aeruginosa in cystic fibrosis lungs. LL-37 disrupts biofilm at two levels: it penetrates the extracellular matrix of established biofilms and kills embedded cells, and it interferes with quorum sensing — the bacterial cell-to-cell communication that coordinates biofilm formation in the first place (Overhage et al., 2008). This anti-quorum sensing mechanism explains why sub-lethal concentrations of LL-37 reduce biofilm formation even without full bacterial killing. Organisms with documented LL-37 biofilm sensitivity include S. aureus, P. aeruginosa, and C. albicans.

Want to understand how to stack immune peptides with recovery peptides? The Peptide Stacking Guide: Advanced Protocols covers combination protocols for $14.99.

Immune Health Benefits

Upper Respiratory Defense

LL-37 is one of the primary host defense peptides in airway surface liquid. Its concentration in the respiratory epithelium is a key variable determining susceptibility to respiratory pathogens.

Influenza A: LL-37 directly inactivates influenza A virions — the positively-charged helical peptide disrupts the viral envelope lipid bilayer, which carries negative charge similar to bacterial membranes (Tripathi et al., 2013). This is not immune activation against influenza; it is direct mechanical inactivation before the virus can infect epithelial cells.

RSV: Respiratory syncytial virus (a major cause of lower respiratory illness in infants and immunocompromised adults) is susceptible to LL-37-mediated inactivation via similar membrane disruption mechanisms, with in vitro data demonstrating reduced viral infectivity at physiological-range concentrations.

SARS-CoV-2: At higher concentrations, LL-37 has demonstrated spike protein binding and partial neutralization in cell-free assays (Mustafa et al., 2020). This is preliminary in vitro data and does not establish clinical antiviral efficacy against COVID-19. The mechanistic plausibility is real; the clinical translation is unproven.

Sepsis protection. LPS scavenging is one of LL-37's clearest anti-inflammatory applications. In gram-negative sepsis, LPS released from dying bacteria activates TLR4, triggering the cytokine cascade that causes septic shock. LL-37 binds LPS with high affinity and prevents TLR4 engagement — functionally removing endotoxin from the inflammatory signaling pool. Numerous animal studies have demonstrated reduced sepsis mortality with LL-37 administration; human data is limited to mechanistic studies, not mortality trials.

Post-antibiotic recovery. Antibiotics sterilize infection but do not restore damaged mucosal epithelium or disrupted microbiome architecture. LL-37's gut barrier effects — ZO-1/occludin upregulation, selective antimicrobial pressure favoring commensal restoration — position it as a logical support compound during antibiotic recovery, particularly for patients with IBD or post-infectious gut dysbiosis.

Gut Health

Leaky Gut and Intestinal Permeability

The term "leaky gut" describes the clinical and research concept of increased intestinal permeability — the passage of bacterial fragments, toxins, and undigested proteins through the gut epithelium into systemic circulation. LL-37 addresses this at the molecular level by upregulating tight junction proteins that hold the epithelial barrier together.

What's notable about the LL-37 mechanism in the gut is its dual action: it simultaneously acts as a selective antimicrobial (killing pathogens that damage the epithelium) and as an epithelial trophic factor (directly strengthening the tight junction protein network). This is different from purely anti-inflammatory approaches — LL-37 doesn't just reduce damage, it reinforces the barrier and removes the microbial drivers of damage at the same time.

LL-37 + Vitamin D3 Synergy for IBD

In inflammatory bowel disease — Crohn's in particular — LL-37 deficiency in the colonic epithelium appears to be a contributing factor, not just a consequence. Vitamin D3 supplementation has demonstrated measurable increases in colonic LL-37 expression in IBD patients (Raftery et al., 2015). This creates a practical therapeutic window: optimizing vitamin D status in IBD patients is one of the few interventions with a clear mechanistic rationale for addressing the upstream cause of LL-37 deficiency rather than supplementing around it.

For patients who want to address both levels — vitamin D optimization plus direct LL-37 support — the combination has logical complementarity. Vitamin D raises endogenous LL-37 production; exogenous LL-37 fills any remaining gap in the epithelial defense layer.

LL-37 vs. BPC-157 for Gut Health

Both LL-37 and BPC-157 are studied for gut repair, but they work through entirely different mechanisms — understanding the distinction matters for building the right protocol.

LL-37 works via epithelial defense and barrier reinforcement. It kills luminal pathogens, upregulates tight junction proteins, and maintains the selective permeability of the gut epithelium. It is primarily a maintenance and defense molecule — keeping the epithelium intact and the microbial ecology in order.

BPC-157 works via angiogenesis and growth factor signaling. Its primary gut effects are through VEGFR2-mediated new blood vessel formation, which accelerates mucosal healing in injured tissue, and through influence on NO synthesis, which improves gut motility and reduces inflammatory cytokine signaling. BPC-157 is primarily a repair molecule — accelerating recovery from existing damage.

The practical implication: for active inflammatory gut disease or post-injury repair, BPC-157 is the primary tool. For maintaining barrier integrity, preventing recurrence, and addressing underlying LL-37 deficiency in IBD patients, LL-37 is the more targeted choice. For serious gut protocols, they are genuinely complementary rather than substitutes. The Repair & Recovery Hub covers BPC-157 combination protocols in depth.

Skin and Wound Healing

Chronic Wound Clearance and Tissue Regrowth

In chronic wounds — diabetic foot ulcers, venous ulcers, pressure injuries — two things are typically wrong: pathogen biofilm preventing healing, and impaired tissue regeneration signals. LL-37 addresses both. Its anti-biofilm activity (particularly against S. aureus and P. aeruginosa, the most common chronic wound pathogens) clears the microbial obstacle, while its FPR2-mediated keratinocyte migration and VEGF upregulation drive re-epithelialization of the wound bed.

Multiple preclinical studies in diabetic animal models have demonstrated accelerated wound closure with topical LL-37 application. The clinical translation has been explored in small trials — Ramos et al. (2011) demonstrated improved wound area reduction with topical LL-37 in venous ulcers compared to placebo — but large-scale RCT data remains limited. The mechanism is well-established; the clinical evidence base is real but early-stage.

The Rosacea Paradox

LL-37 is directly implicated in rosacea pathogenesis — and this is one of the clearest examples of why "more is not always better" with host defense peptides.

In rosacea-affected skin, hCAP18 is overexpressed and abnormally processed by kallikrein-5 (a serine protease upregulated in rosacea lesions) to produce LL-37 fragments that are more pro-inflammatory than the intact peptide. These fragments drive the TLR2-mediated inflammation responsible for rosacea's characteristic redness, papules, and pustules (Yamasaki et al., 2007). Critically: it is not the presence of LL-37 that causes the problem, but the dysregulated overproduction and aberrant cleavage of hCAP18.

The honest caveat: Anyone with existing rosacea or rosacea-prone skin should approach exogenous LL-37 with caution. The inflammatory mechanism is real, the risk is dermatologically plausible, and the appropriate response is to discuss with a dermatologist before proceeding with any LL-37 protocol, topical or systemic.

Acne

C. acnes (Cutibacterium acnes) is susceptible to LL-37 in vitro — the peptide's antimicrobial activity extends to this gram-positive organism. Lower LL-37 expression in acne-prone skin is associated with increased C. acnes colonization. However, the same inflammatory signaling that causes rosacea can be triggered by LL-37 at inflammatory doses, meaning there is a therapeutic window: enough LL-37 to suppress C. acnes, not so much as to drive the inflammatory cytokine response that worsens acne vulgaris. The research in acne is exploratory; this is not a validated clinical indication.

Dosing Protocols

The following dosing information reflects what appears in the research chemical community for LL-37 protocols. There are no approved clinical dosing guidelines for exogenous LL-37 in healthy individuals. All dosing information is extrapolated from animal studies, the limited human pharmacokinetic data that exists, and practitioner protocols shared in research communities.

Route: Subcutaneous (SubQ) or intramuscular (IM) injection. Intranasal for respiratory applications.

General Range: 100–500 mcg per injection

Cycling: 5 days on / 2 days off. Cycling is used to prevent receptor desensitization at FPR2 and to allow the immune system's LL-37 signaling networks to reset between active dosing periods. Extended continuous protocols carry a theoretical risk of adaptive downregulation of endogenous LL-37 production — the same logic that governs cycling of growth hormone secretagogues.

Protocol 1: Acute Immune Support

• Dose: 200–300 mcg SubQ once daily
• Duration: 10–14 days
• Timing: During active infection, post-viral recovery, or post-antibiotic course
• Rationale: Short, higher-dose protocol to provide direct antimicrobial coverage and LPS scavenging during active immune challenge

Protocol 2: Chronic Gut Barrier Protocol

• Dose: 100–200 mcg SubQ once daily
• Duration: 4–8 weeks, 5-on/2-off cycling
• Timing: Morning administration
• Rationale: Sustained lower-dose protocol for gut barrier maintenance, IBD support, and leaky gut repair. Often co-administered with vitamin D3 (2,000–5,000 IU/day) to optimize endogenous hCAP18 transcription simultaneously

Protocol 3: Intranasal (Respiratory)

• Dose: 200 mcg in sterile saline via nasal spray
• Timing: 1–2x daily during respiratory season or post-exposure
• Rationale: Direct delivery to the airway surface liquid, where LL-37 acts on respiratory pathogens. This is the delivery route most closely mimicking the peptide's endogenous mechanism in lung defense

Storage

LL-37 is stable as a lyophilized (freeze-dried) powder at -20°C for 12–18 months, typically in sealed vials under inert atmosphere. Once reconstituted in bacteriostatic water, stability is approximately 28 days at 4°C. Avoid repeated freeze-thaw cycles of reconstituted solution. Store away from light.

Safety

Toxicity profile. In preclinical studies, LL-37 has a favorable safety profile at therapeutic dose ranges. Cytotoxicity to mammalian cells in vitro is documented only at concentrations substantially higher than those relevant to therapeutic protocols — the electrostatic selectivity for bacterial over mammalian membranes that underlies its antimicrobial mechanism provides a meaningful therapeutic index.

Rosacea and psoriasis aggravation risk. This is the most clinically important safety signal for exogenous LL-37. As described in the skin section: LL-37 overexpression drives the inflammatory pathology in both rosacea and psoriasis. Individuals with either condition should treat LL-37 as contraindicated or high-risk without dermatological supervision. This is not a theoretical concern; it is a mechanistically well-established risk pathway.

No long-term human data. There are no published long-term trials on exogenous LL-37 administration in healthy humans. The research community's experience is limited to short trials in wound care, small mechanistic studies, and the research chemical user base. The absence of reported toxicity at standard doses is reassuring; the absence of long-term safety data means unknowns remain.

Immune overstimulation risk. At high doses or in individuals with autoimmune predisposition, LL-37's pro-inflammatory activity at lower concentrations could theoretically aggravate autoimmune conditions. This is poorly characterized in the clinical literature but is mechanistically plausible given LL-37's documented role in driving neutrophil chemotaxis and mast cell activation.

Research chemical status. LL-37 is not FDA-approved for any human therapeutic indication. It is available as a research peptide and is sold legally for research purposes in the United States and most Western jurisdictions. It is not scheduled. Regulatory status mirrors BPC-157 and other well-known research peptides — neither controlled nor approved; used by individuals under their own discretion.

Frequently Asked Questions

How does LL-37 differ from BPC-157 for gut health?

They operate through completely different mechanisms and address different phases of gut dysfunction. LL-37 maintains gut barrier integrity by upregulating tight junction proteins (ZO-1, occludin) and providing selective antimicrobial pressure that protects the epithelium from pathogen-driven damage. It is primarily a defense and maintenance molecule. BPC-157 is a repair molecule — it accelerates mucosal healing in already-damaged tissue via angiogenesis (VEGFR2 signaling) and growth factor pathways. For maintaining a healthy gut and preventing IBD recurrence, LL-37 is the more targeted choice. For recovering from active gut injury — post-NSAID damage, post-infectious mucosal injury, surgery — BPC-157 is the primary tool. For serious gut protocols, they are complementary, not interchangeable. See the full BPC-157 research guide for the mechanistic comparison.

Can I stack LL-37 with Thymosin Alpha-1?

Yes — and this is one of the most rationally designed immune stacks available. LL-37 operates at the innate immune layer (front-line antimicrobial defense, epithelial barriers, neutrophil recruitment), while Thymosin Alpha-1 works at the adaptive immune layer (T-cell maturation, dendritic cell activation, NK cell enhancement). They target different arms of the immune system with no overlapping mechanisms and no known antagonism. The Thymalin guide covers the thymic peptide layer — combining all three (LL-37 + TA-1 + Thymalin) gives you innate, adaptive, and thymic immune support simultaneously.

Does vitamin D increase LL-37 naturally?

Yes — and this is one of the most clinically well-established links between a nutrient and a host defense peptide. 1,25-dihydroxyvitamin D3 (the active hormonal form) drives direct transcription of the CAMP gene via the vitamin D response element in the CAMP promoter. Liu et al. (2006) demonstrated that vitamin D-deficient macrophages had significantly lower LL-37 production, and that supplementation increased it. Raftery et al. (2015) showed increased colonic LL-37 expression in IBD patients following vitamin D3 supplementation. Optimizing vitamin D status — keeping 25-OH vitamin D above 40–60 ng/mL — is the most evidence-supported natural approach to maximizing endogenous LL-37 production.

Is LL-37 the same as cathelicidin?

LL-37 is the human cathelicidin — they refer to the same molecule. The terminology can be confusing: "cathelicidin" is the family name (all members share a conserved N-terminal "cathelin" domain in their precursor protein). In most mammals, multiple cathelicidins exist. In humans, the cathelicidin family has only one member: the CAMP gene, producing hCAP18, which is cleaved to yield the active peptide LL-37. So "LL-37," "human cathelicidin," and "hCAP18-derived peptide" all refer to the same molecule at different stages of its biosynthetic processing.

What is LL-37's half-life?

The pharmacokinetic data on exogenous LL-37 in humans is sparse. In biological fluids, LL-37 is susceptible to proteolytic degradation, particularly by metalloproteinases and neutrophil-derived elastase. In vitro half-life in serum is estimated at 30–90 minutes. In vivo half-life after subcutaneous injection is estimated at 1–3 hours, based on tissue distribution studies in animal models. This short half-life is one reason researchers typically dose once daily rather than less frequently, and why intranasal delivery (which deposits the peptide directly at the target mucosal surface) is preferred for respiratory applications.

Conclusion

LL-37 sits at an unusual intersection in the peptide landscape: it is simultaneously an endogenous host defense molecule (your body makes it), a vitamin D-dependent immune output (your nutritional status directly controls its production), and a multifunctional peptide with mechanistically validated effects across five distinct biological pathways. That combination of properties makes it one of the most interesting immune peptides available — and one of the most important to understand correctly.

The evidence base is strongest for its direct antimicrobial activity, LPS scavenging in sepsis models, and gut barrier maintenance in IBD. Wound healing and respiratory defense have solid mechanistic foundations with early clinical data. The anti-biofilm activity is preclinical but mechanistically clear. Cognitive or systemic longevity applications are speculative at current evidence levels.

The inflammatory paradox is real and requires honest acknowledgment: LL-37 is not a "more is better" molecule. Its dose-dependent dual immune role, its implication in rosacea and psoriasis, and the absence of long-term human safety data all argue for conservative, well-structured protocols — not aggressive high-dose continuous use.

For anyone building a comprehensive immune stack, the Immune Health Peptides Hub is the right starting point — LL-37 for innate defense, Thymosin Alpha-1 for adaptive immune support, Thymalin for thymic regeneration. These three operate at genuinely different immune layers and combine into something more coherent than any single peptide alone.

If you're new to peptides entirely and want to understand where immune peptides fit in the broader landscape, the Beginner's Guide lays out the foundational logic.

Ready to build a complete protocol? The Peptide 101: Complete Bundle gives you everything — beginner's guide + stacking protocols — for $19.99.

The Complete Bundle covers LL-37 combination protocols, immune stacking logic with Thymosin Alpha-1 and Thymalin, and the gut health protocols that combine LL-37's barrier defense with BPC-157's repair mechanisms. Everything needed to move from understanding the mechanism to running an evidence-based protocol.

This content is for educational purposes only and does not constitute medical advice. LL-37 is a research peptide and is not FDA-approved for any human therapeutic indication. The dosing protocols described are derived from preclinical research and research community practice — not from approved clinical guidelines. Consult a qualified healthcare provider before beginning any peptide protocol, particularly if you have inflammatory skin conditions (rosacea, psoriasis), autoimmune disease, or are taking immunosuppressive medications.